On October 19, Pfizer, Inc.'s $43 billion acquisition of cancer drug maker Seagen, Inc. received unconditional approval from the EU antitrust authority. The European Commission stated that the proposed merger would not raise competition concerns or have a negative impact on treatment prices.
On March 13, Pfizer, Inc. announced that it had reached a definitive merger agreement with biotechnology company Seagen, Inc. Under the agreement, Pfizer will acquire Seagen for $229 per share in cash, with a total enterprise value of $43 billion. The boards of both companies have unanimously approved the transaction.